This segment focuses on the research, development, and clinical trials of GP2, an immunotherapy designed to prevent the recurrence of breast cancer in patients who have undergone surgery. The primary activity involves conducting Phase III clinical trials (FLAMINGO-01) to evaluate the efficacy and safety of GP2. The technology utilizes a peptide-based immunotherapy approach, targeting the HER2/neu protein. The goal is to improve patient outcomes by reducing the risk of breast cancer recurrence. Market positioning is centered on addressing a significant unmet medical need in the breast cancer treatment landscape. Future opportunities include expanding the application of GP2 to other HER2/neu-expressing cancers and securing regulatory approvals for commercialization. Partnerships with organizations like Unicancer, GEICAM, and GIM are crucial for trial execution and market access. Regulatory aspects involve adherence to FDA guidelines and other international regulatory bodies.